IllnessLung cancer, SCLC; susceptibility + protection

Summary

Short information

A curated panel containing 5 genes for the comprehensive analysis of the genetic susceptibility/protection concerning SCLC lung carcinoma

LP2468

Number of genes

5 Accredited laboratory test

Examined sequence length

0,0 kb (Core-/Core-canditate-Genes)
11,9 kb (Extended panel: incl. additional genes)

Analysis Duration

on request

Material

EDTA-anticoagulated blood (3-5 ml)

Diagnostic indications

NGS +

Gene panel

Selected genes

Name	Exon Length (bp)	OMIM-G	Referenz-Seq.	Heredity
CASP8	1395	601763	NM_001080124.2	Ass
CYP2A6	1485	122720	NM_000762.6	AD
EGFR	3633	131550	NM_005228.5	AD, SMu, Sus
ERCC6	4482	609413	NM_000124.4	AD, Sus
FASLG	846	134638	NM_000639.3	Sus

Informations about the disease

Clinical Comment

Highly aggressive accounting for 10-15% of lung cancers, rapid growth, early metastasis, usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, neurological + endocrine paraneoplastic syndromes; primarily in elderly people with long-term tobacco exposure. Associations with spezific genes/markers are often limited to certain populations.

Synonyms

Lung cancer, protection against (CASP8)
Lung cancer, resistance to (CYP2A6)
Lung cancer, somatic (MAP3K8, PPP2R1B, KRAS)
Lung cancer, susceptibility to (ERCC6, FASLG)

Heredity, heredity patterns etc.

OMIM-Ps

Multiple OMIM-Ps

ICD10 Code

Bioinformatics and clinical interpretation

No text defined